scholarly journals Nanofiber‐expanded human umbilical cord blood–derived CD 34 + cell therapy accelerates cutaneous wound closure in NOD / SCID mice

2014 ◽  
Vol 18 (4) ◽  
pp. 685-697 ◽  
Author(s):  
Suman Kanji ◽  
Manjusri Das ◽  
Reeva Aggarwal ◽  
Jingwei Lu ◽  
Matthew Joseph ◽  
...  
2002 ◽  
Vol 30 (8) ◽  
pp. 870-878 ◽  
Author(s):  
Willy A Noort ◽  
Alwine B Kruisselbrink ◽  
Pieternella S in't Anker ◽  
Marjolein Kruger ◽  
Rutger L van Bezooijen ◽  
...  

Blood ◽  
1998 ◽  
Vol 92 (11) ◽  
pp. 4013-4022 ◽  
Author(s):  
Paula B. van Hennik ◽  
Monique M.A. Verstegen ◽  
Marti F.A. Bierhuizen ◽  
Ana Limón ◽  
Albertus W. Wognum ◽  
...  

Abstract Purified CD34+ and CD34+CD38− human umbilical cord blood (UCB) cells were transduced with the recombinant variant of Moloney murine leukemia virus (MoMLV) MFG-EGFP or with SF-EGFP, in which EGFP expression is driven by a hybrid promoter of the spleen focus-forming virus (SFFV) and the murine embryonic stem cell virus (MESV). Infectious MFG-EGFP virus was produced by an amphotropic virus producer cell line (GP+envAm12). SF-EGFP was produced in the PG13 cell line pseudotyped for the gibbon ape leukemia virus (GaLV) envelope proteins. Using a 2-day growth factor prestimulation, followed by a 2-day, fibronectin fragment CH-296–supported transduction, CD34+ and CD34+CD38− UCB subsets were efficiently transduced using either vector. The use of the SF-EGFP/PG13 retroviral packaging cell combination consistently resulted in twofold higher levels of EGFP-expressing cells than the MFG-EGFP/Am12 combination. Transplantation of 105 input equivalent transduced CD34+ or 5 × 103input equivalent CD34+CD38− UCB cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice resulted in median engraftment percentages of 8% and 5%, respectively, which showed that the in vivo repopulating ability of the cells had been retained. In addition, mice engrafted after transplantation of transduced CD34+ cells using the MFG-EGFP/Am12 or the SF-EGFP/PG13 combination expressed EGFP with median values of 2% and 23% of human CD45+ cells, respectively, which showed that the NOD/SCID repopulating cells were successfully transduced. EGFP+ cells were found in all human hematopoietic lineages produced in NOD/SCID mice including human progenitors with in vitro clonogenic ability. EGFP-expressing cells were also detected in the human cobblestone area–forming cell (CAFC) assay at 2 to 6 weeks of culture on the murine stromal cell line FBMD-1. During the transduction procedure the absolute numbers of CAFC week 6 increased 5- to 10-fold. The transduction efficiency of this progenitor cell subset was similar to the fraction of EGFP+ human cells in the bone marrow of the NOD/SCID mice transplanted with MFG-EGFP/Am12 or SF-EGFP/PG13 transduced CD34+ cells, ie, 6% and 27%, respectively. The study thus shows that purified CD34+ and highly purified CD34+CD38− UCB cells can be transduced efficiently with preservation of repopulating ability. The SF-EGFP/PG13 vector/packaging cell combination was much more effective in transducing repopulating cells than the MFG-EGFP/Am12 combination.


PLoS ONE ◽  
2012 ◽  
Vol 7 (6) ◽  
pp. e39365 ◽  
Author(s):  
Reeva Aggarwal ◽  
Jingwei Lu ◽  
Suman Kanji ◽  
Matthew Joseph ◽  
Manjusri Das ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document